Ala Eddin Sagar/LinkedIn
Mar 22, 2026, 16:21
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center – Madinah, shared a post on LinkedIn:
Apixaban or rivaroxaban for acute VTE?
This study is one of three papers discussed in this week’s episode of This Week in Pulmonary and Critical Care Medicine.
We review:
- A randomized trial comparing apixaban vs rivaroxaban for VTE
- An ICU study on oscillatory airway therapy in ventilated patients
- A teaching discussion on how mitral valve disease affects the lungs
Curious how others are interpreting the DOAC trial.
Do you favor apixaban or rivaroxaban for acute VTE?
Stay updated with Hemostasis Today.
-
Mar 22, 2026, 16:14Andre W. Bourgoyne: Anemia Management as a Comprehensive Hospital Performance Strategy
-
Mar 22, 2026, 16:03Fibrinogen-Guided Management of Postpartum Hemorrhage – Transfusion Medicine KMC Manipal
-
Mar 22, 2026, 15:48Simon Senanu: Diagnostic Significance of Target Cells in Peripheral Blood Smear
-
Mar 22, 2026, 15:43Hayley Evans: What If The Decision Support System Is Part of The Problem?
-
Mar 22, 2026, 15:29Archit Pandharipande: The Burden and Impact of Heavy Menstrual Bleeding in Adolescents with Bleeding Disorders
-
Mar 22, 2026, 15:17Mamtha Balla: Mastering the Lab and Clinical Connection in Hemostasis and Thrombosis
-
Mar 22, 2026, 14:53Daniel Torrent: Amputation Is Not Inevitable in CLTI
-
Mar 22, 2026, 14:46Francisco Chacón-Lozsán: PE Is The New STEMI, But Are We Treating It Too Aggressively?
-
Mar 22, 2026, 14:26Hussien Hishmat: Pulmonary Embolism – How Does Risk Dictate Management